Monitoring Early Breast Cancer Response To Neoadjuvant Therapy Using H-Scan Ultrasound Imaging: Preliminary Preclinical Results

Simple item page
dc.contributor.authorKhairalseed, Mawia
dc.contributor.authorJaved, Kulsoom
dc.contributor.authorJashkaran, G.
dc.contributor.authorKim, J. -W
dc.contributor.authorParker, K. J.
dc.contributor.authorHoyt, Kenneth
dc.contributor.utdAuthorHoyt, Kenneth
dc.contributor.utdAuthorKhairalseed, Mawia
dc.contributor.utdAuthorJaved, Kulsoom
dc.date.accessioned2020-02-17T21:53:17Z
dc.date.available2020-02-17T21:53:17Z
dc.date.issued2019-04-17
dc.descriptionDue to copyright restrictions and/or publisher's policy full text access from Treasures at UT Dallas is not available. UTD affiliates may be able to acquire a copy by using the link below to contact university Interlibrary Loan.
dc.description.abstractObjective—H-scan imaging is a new ultrasound technique used to visualize the relative size of acoustic scatterers. The purpose of this study was to evaluate the use of H-scan ultrasound imaging for monitoring early tumor response to neoadjuvant treatment using a preclinical breast cancer animal model. Methods—Real-time H-scan ultrasound imaging was implemented on a programmable ultrasound scanner (Vantage 256; Verasonics Inc., Kirkland, WA) equipped with an L11-4v transducer. Bioluminescence and H-scan ultrasound was used to image luciferase-positive breast cancer–bearing mice at baseline and at 24, 48, and 168 hours after administration of a single dose of neoadjuvant (paclitaxel) or sham treatment. Animals were euthanized at 48 or 168 hours, and tumors underwent histologic processing to identify cancer cell proliferation and apoptosis. Results—Baseline H-scan ultrasound images of control and therapy group tumors were comparable, but the latter exhibited significant changes over the 7-day study (P 0.40, P < .04). Conclusion—Preliminary preclinical results suggest that H-scan ultrasound imaging is a new and promising tissue characterization modality. H-scan ultrasound imaging may provide prognostic value when monitoring early tumor response to neoadjuvant treatment. © 2018 by the American Institute of Ultrasound in Medicine.
dc.description.departmentErik Jonsson School of Engineering and Computer Science
dc.identifier.bibliographicCitationKhairalseed, M., K. Javed, G. Jashkaran, J. -W Kim, et al. 2019. "Monitoring early breast cancer response to neoadjuvant therapy using H-scan ultrasound imaging: Preliminary preclinical results." Journal of Ultrasound In Medicine 38(5): 1259-1268, doi: 10.1002/jum.14806
dc.identifier.issn0278-4297
dc.identifier.issue5
dc.identifier.urihttp://dx.doi.org/10.1002/jum.14806
dc.identifier.urihttps://hdl.handle.net/10735.1/7271
dc.identifier.volume38
dc.language.isoen
dc.publisherJohn Wiley and Sons Ltd.
dc.rights©2018 American Institute of Ultrasound in Medicine
dc.source.journalJournal of Ultrasound In Medicine
dc.subjectApoptosis
dc.subjectCancer
dc.subjectDiagnostic ultrasonic imaging
dc.subjectNeoadjuvant Therapy
dc.subjectCell Death
dc.subjectCell Proliferation
dc.subjectMammals
dc.subjectTumors
dc.subjectBreast--Cancer
dc.titleMonitoring Early Breast Cancer Response To Neoadjuvant Therapy Using H-Scan Ultrasound Imaging: Preliminary Preclinical Results
dc.type.genrearticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
JECS-5911-260899.50-LINK.pdf
Size:
165.94 KB
Format:
Adobe Portable Document Format
Description:
Link to Article
Download

Collections

Hoyt, Kenneth